Exhibit 4.58


 


NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE
OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN
A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE
TO BE SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH
A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.


 


WARRANT
TO PURCHASE COMMON STOCK


 


	Company:	Amyris, Inc., a
                                         Delaware corporation
	Warrant Certificate:  	GW-1
	Number of Shares:	5,000,000
	Class of Stock:	Common Stock
	Warrant Price:	$0.50 per share
	Issue Date:	August 6, 2016
	Expiration Date:	The 1st anniversary of the Issue
                                         Date





















 


THIS
WARRANT CERTIFIES THAT, for good and valuable consideration, GINKGO BIOWORKS, INC. (together with any registered holder from time
to time of this Warrant or any holder of the shares issuable or issued upon exercise of this Warrant, “Holder”)
is entitled to purchase the number of fully paid and nonassessable shares of the class of securities of the Company at the Warrant
Price, all as set forth above and as adjusted pursuant to Article 2 of this Warrant, subject to the provisions and upon the terms
and conditions set forth in this Warrant.


 


ARTICLE
1 EXERCISE.


 


1.1.         
Exercise. This Warrant shall be exercisable for 5,000,000 shares of the
Company’s common stock, par value $0.0001 per share (the “Common Stock”) (the “Shares”).
The number of Shares and the Warrant Price are subject to adjustment as provided herein, and all references to “Shares”
and “Warrant Price” herein shall be deemed to include any such adjustment or series of adjustments.


 


1.2.         
Method of Exercise.


 


(a)           
Mechanics. This Warrant may be exercised by the Holder at any time on or
after the Issue Date (an “Exercise Date”), in whole or in part, by delivery (whether via facsimile or otherwise)
of a written notice, in the form attached hereto as Exhibit A (the “Exercise Notice”), of the Holder’s
election to exercise this Warrant. Within one (1) Trading Day following an


 






     


     


    




 


exercise
of this Warrant as aforesaid, the Holder shall deliver payment to the Company of an amount equal to the Warrant Price in effect
on the date of such exercise multiplied by the number of Shares as to which this Warrant was so exercised (the “Aggregate
Warrant Price”) in cash or via wire transfer of immediately available funds if the Holder did not notify the Company
in such Exercise Notice that such exercise was made pursuant to a Cashless Exercise (as defined in Section 1.3). The Holder shall
not be required to deliver the original of this Warrant in order to effect an exercise hereunder. Execution and delivery of an
Exercise Notice with respect to less than all of the Shares shall have the same effect as cancellation of the original of this
Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Shares. Execution and delivery
of an Exercise Notice for all of the then-remaining Shares shall have the same effect as cancellation of the original of this
Warrant after delivery of the Shares in accordance with the terms hereof. On or before the later of the third (3rd) Trading Day
following the date on which the Company has received such Exercise Notice and one (1) Trading Day after the Company’s receipt
of the Aggregate Warrant Price (or valid notice of a Cashless Exercise) (such later date, the “Share Delivery Deadline”),
the Company shall, (X) provided that the Company’s Common Stock transfer agent (the “Transfer Agent”)
is participating in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program, upon the
request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such
exercise to the Holder’s or its designee’s balance account with DTC through its Deposit/Withdrawal at Custodian system,
or (Y) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, upon the request of the
Holder, issue and deliver (via reputable overnight courier) to the address as specified in the Exercise Notice, a certificate,
registered in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder shall be entitled
pursuant to such exercise. Upon delivery of an Exercise Notice, the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Shares with respect to which this Warrant has been exercised, irrespective of the date such
Shares are credited to the Holder’s DTC account or the date of delivery of the certificates evidencing such Shares (as the
case may be). If this Warrant is submitted in connection with any exercise pursuant to this Section 1 and the number of Shares
represented by this Warrant submitted for exercise is greater than the number of Shares being acquired upon an exercise and upon
surrender of this Warrant to the Company by the Holder, then the Company shall as soon as practicable and in no event later than
three (3) business days after any exercise and at its own expense, issue and deliver to the Holder (or its designee) a new Warrant
representing the right to purchase the number of Shares purchasable immediately prior to such exercise under this Warrant, less
the number of Shares with respect to which this Warrant is exercised. No fractional shares of Common Stock are to be issued upon
the exercise of this Warrant, but rather the number of shares of Common Stock to be issued shall be rounded down to the nearest
whole number. The Company shall pay any and all transfer, stamp, issuance and similar taxes, costs and expenses (including, without
limitation, fees and expenses of the Transfer Agent) that may be payable with respect to the issuance and delivery of Shares upon
exercise of this Warrant. Notwithstanding the foregoing, the Company’s failure to deliver Shares to the Holder on or prior
to Share Delivery Deadline shall not be deemed to be a breach of this Warrant, provided that the Company is in compliance with
the other provisions of this Warrant, including without limitation Section 1.2(b).


 






    	2



     


    

(b)           
Company’s Failure to Timely Deliver Securities. If the Company shall
fail, for any reason or for no reason, on or prior to the Share Delivery Deadline, if the Transfer Agent is not participating
in the DTC Fast Automated Securities Transfer Program, to issue and deliver to the Holder (or its designee) a certificate for
the number of Shares to which the Holder is entitled and register such Shares on the Company’s share register or, if the
Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, to credit the balance account of the Holder
or the Holder’s designee with DTC for such number of Shares to which the Holder is entitled upon the Holder’s exercise
of this Warrant (as the case may be), and if on or after such Share Delivery Deadline the Holder purchases (in an open market
transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of all or any portion of the
number of shares of Common Stock issuable upon such exercise that the Holder anticipated receiving from the Company (a “Buy-In”),
then, in addition to all other remedies available to the Holder, the Company shall, within three (3) business days after the Holder’s
request and in the Holder’s discretion, either (i) pay cash to the Holder in an amount equal to the Holder’s total
purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased
(including, without limitation, by any other Person in respect, or on behalf, of the Holder) (the “Buy-In Price”),
at which point the Company’s obligation to so issue and deliver such certificate (and to issue such shares of Common Stock)
or credit the balance account of such Holder or such Holder’s designee, as applicable, with DTC for the number of Shares
to which the Holder is entitled upon the Holder’s exercise hereunder (as the case may be) (and to issue such Shares) shall
terminate and the applicable Exercise Notice shall be disregarded as if never submitted by the Holder, or (ii) promptly honor
its obligation to so issue and deliver to the Holder a certificate or certificates representing such Shares or credit the balance
account of such Holder or such Holder’s designee, as applicable, with DTC for the number of Shares to which the Holder is
entitled upon the Holder’s exercise hereunder (as the case may be) and pay cash to the Holder in an amount equal to the
excess (if any) of the Buy-In Price over the product of (A) such number of Shares multiplied by (B) the average closing price
of the Common Stock across all Trading Days during the period commencing on the date of the applicable Exercise Notice and ending
on the date of such issuance and payment under this clause (ii). Nothing shall limit the Holder’s right to pursue any other
remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or
injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock
(or to electronically deliver such shares of Common Stock) upon the exercise of this Warrant as required pursuant to the terms
hereof.


 


1.3.         
Cashless Exercise Right. In lieu of exercising this Warrant by making the
cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Warrant Price pursuant
to Article 1.2, Holder may elect instead to receive upon
such exercise the “Net Number” of shares of Common Stock determined according to the
following formula (a “Cashless Exercise”):


 





	 	Net Number = (A x B) - (A x C)	 
	 	B	 












 


For purposes
of the foregoing formula:


 


A= the total
number of shares with respect to which this Warrant is then being exercised.


 






    	3



     


    

B=
the fair market value of each Share, which shall be (i) the average for the five Trading Days immediately prior to the date of
determination thereof of the last reported sale price regular way on each such day, (ii) in the case no such sale takes place
on any such day, the average of the reported closing bid and asked prices regular way of the shares of Common Stock on such day,
in each case as quoted on the Principal Market, as reported by Bloomberg or such other principal securities exchange or inter-dealer
quotation system on which the shares of Common Stock are then traded, or (iii) in the case the shares of Common Stock are not
traded publically on the Principal Market, the value mutually agreed up by the Company and the Holder.


 


C= the Warrant Price
then in effect for the applicable Shares at the time of such exercise.


 


1.4.         
Delivery of Certificate and New Warrant. Promptly after Holder exercises
or converts this Warrant, and, if applicable, the Company receives payment of the aggregate Warrant Price, the Company shall deliver
to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised or converted and has not expired,
a new Warrant representing the Shares not so acquired. Holder shall be deemed to own and have all of the rights associated with
any Shares or other securities or property to which it is entitled pursuant to this Warrant upon the exercise or conversion of
the Warrant in accordance with this Article 1.


 


1.5.         
Replacement of Warrants. On receipt of evidence reasonably satisfactory
to the Company of the loss, theft, destruction or mutilation of this Warrant and in the case of loss, theft or destruction, on
delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of mutilation on
surrender and cancellation of this Warrant, the Company shall execute and deliver, in lieu of this Warrant, a new warrant of like
tenor.


 


1.6.         
Treatment of Warrant Upon Acquisition of Company.


 


1.6.1      
“Acquisition”. For the purpose of this Warrant, “Acquisition”
shall mean the occurrence of any of the following: (i) the consolidation of the Company with, or the merger of the Company
with or into, another “person” (as such term is used in Rule 13d-3 and Rule 13d-5 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”)), or the sale, lease, exclusive license, transfer, conveyance or other
disposition, in one or a series of related transactions, of all or substantially all of the assets of the Company and its Subsidiaries
taken as a whole, or the consolidation of another “person” with, or the merger of another “person” into,
the Company, other than in each case pursuant to a transaction in which the “persons” that “beneficially owned”
(as such term is defined in Rule 13d-3 and Rule 13d-5 under the Exchange Act), directly or indirectly, the Voting Shares (as defined
below) of the Company immediately prior to the transaction “beneficially own”, directly or indirectly, Voting Shares
representing at least a majority of the total voting power of all outstanding classes of voting stock of the surviving or transferee
person; (ii) the adoption by the Company of a plan relating to the liquidation or dissolution of the Company; (iii) the
consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that any “person”
becomes the “beneficial owner” directly or indirectly, of more than 50% of the Voting Shares of the Company (measured
by voting power rather than number of shares); or (iv) during any period of 24 consecutive months, a majority of the members of
the Company’s Board of Directors cease to be composed of individuals (A) who were members of the Board of Directors on the
first day of such period, (B) whose election, nomination or appointment to the Board of Directors was approved by at least a majority
of the individuals referred to in clause (A) above or (C) whose election, nomination or appointment to the Board was approved
by at least a majority of the individuals referred to in clauses (A) and (B) taken together. For the purposes of this Article
1.6.1, “Voting Shares” of any person shall mean capital shares or capital stock of such person which ordinarily
has voting power for the election of directors (or persons performing similar functions) of such person.


 






    	4



     


    







 


1.6.2      
Notice of Acquisition. The Company shall provide Holder with written
notice of an Acquisition (together with such reasonable information as Holder may request in connection with such contemplated
Acquisition giving rise to such notice), which is to be delivered to Holder not less than ten (10) days prior to the closing of
the proposed Acquisition.


 


1.6.3      
Treatment of Warrant at Cash/Public Acquisition. In the event of an Acquisition
in which the consideration to be received by the Company’s stockholders consists solely of cash, solely of Marketable Securities
or a combination of cash and Marketable Securities (a “Cash/Public Acquisition”), and the fair market value
of one Share as determined in accordance with Section 1.3 above would be greater than the Warrant Price in effect on such
date immediately prior to such Cash/Public Acquisition, and Holder has not exercised this Warrant pursuant to Article 1 above
as to all Shares, then this Warrant shall automatically be deemed to be exercised as a Cashless Exercise pursuant to Section 1.3
above as to all Shares effective immediately prior to and contingent upon the consummation of a Cash/Public Acquisition. In the
event of a Cash/Public Acquisition where the fair market value of one Share as determined in accordance with Section 1.3
above would be less than the Warrant Price in effect immediately prior to such Cash/Public Acquisition, then this Warrant will
expire immediately prior to the consummation of such Cash/Public Acquisition, unless the Holder elects to exercise the Warrant
prior to the consummation of such Cash/Public Acquisition.


 


1.6.4      
Treatment of Warrant at Acquisition other than Cash/Public Acquisition.
Upon the closing of any Acquisition other than a Cash/Public Acquisition, unless Holder agrees otherwise in writing (but without
obligation to do so), the acquiring, surviving or successor entity shall assume the obligations of this Warrant, and this Warrant
shall thereafter be exercisable for the same securities and/or other property as would have been paid for the Shares issuable
upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition,
subject to further adjustment from time to time in accordance with the provisions of this Warrant.


 


1.7.         
Insufficient Authorized Shares. If at any time while the Warrant remains
outstanding the Company does not have a sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation
to reserve for issuance upon exercise of the Warrant at least a number of shares of Common Stock equal to 100% (the “Required
Reserve Amount”) of the number of shares of Common Stock as shall from time to time be necessary to effect the exercise
of the Warrant then outstanding, then the Company shall immediately take all action necessary to increase the Company’s
authorized shares of Common Stock to an amount sufficient to allow the Company to reserve the Required Reserve Amount for the
Warrant then outstanding.


 






    	5



     


    







 


ARTICLE
2 ADJUSTMENTS TO THE SHARES.


 


2.1.         
Stock Dividends, Splits, Etc. If the Company declares or pays a dividend
on the Shares payable in common stock of the Company, or other securities, then upon exercise of this Warrant, for each Share
acquired, Holder shall receive, without cost to Holder, the total number and kind of shares of common stock of the Company to
which Holder would have been entitled had Holder owned the Shares of record as of the date the dividend occurred. If the Company
subdivides the Shares by reclassification or otherwise into a greater number of shares or takes any other action which increases
the amount of stock for which this Warrant is exercisable, the number of Shares subject to the Warrant shall be proportionately
increased and the Warrant Price shall be proportionately decreased. If the outstanding shares are combined or consolidated, by
reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the number
of Shares subject to the Warrant shall be proportionately decreased.


 


2.2.         
Reclassification, Exchange, Combinations or Substitution. Upon any reclassification,
exchange, substitution, reorganization, recapitalization or other event that results in a change of the number and/or class of
the securities issuable upon exercise or conversion of this Warrant (other than an Acquisition which is subject to the provisions
of Article 1.6), Holder shall be entitled to receive, upon exercise or conversion of this Warrant the number and kind of securities
and property that Holder would have received for the Shares if this Warrant had been exercised immediately before such reclassification,
exchange, substitution, or other event. The Company or its successor shall promptly issue to Holder an amendment to this Warrant
setting forth the number and kind of such new securities or other property issuable upon exercise or conversion of this Warrant
as a result of such reclassification, exchange, substitution or other event that results in a change of the number and/or class
of securities issuable upon exercise or conversion of this Warrant. The amendment to this Warrant shall provide for adjustments
which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article 2 including, without
limitation, adjustments to the Warrant Price and to the number of securities or property issuable upon exercise of the new Warrant.
The provisions of this Article 2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other events.


 


2.3.         
Other Adjustment Events. If any event occurs of the type contemplated by
the provisions of this Article 2 but not expressly provided for by such provisions, then the Company’s Board of Directors
will make an appropriate adjustment in the Warrant Price and the number of Warrant Shares so as to protect the rights of the Holder;
provided that no such adjustment pursuant to this Article 2.4 will increase the Warrant Price or decrease the number of Shares
as otherwise determined pursuant to this Article 2.


 


2.4.         
No Impairment. Without the consent of the Holder, the Company shall not
by amendment of its Certificate of Incorporation or through a reorganization, transfer of assets, consolidation, merger, dissolution,
issue, or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms to be observed or performed under this Warrant by the Company, but shall at all times in good faith assist in carrying out
of all the provisions of this Article 2 and in taking all such action as may be necessary or appropriate to protect Holder’s
rights under this Article 2 against impairment.


 






    	6



     


    







 


2.5.         
Fractional Shares. No fractional Shares shall be issuable upon exercise
or conversion of this Warrant and the number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional
share interest arises upon any exercise or conversion of the Warrant, the Company shall eliminate such fractional share interest
by paying Holder in cash equivalent to the amount computed by multiplying the fractional interest by the fair market value of
a full Share (as determined pursuant to Section 1.3 of this Warrant).


 


2.6.         
Certificate as to Adjustments. Upon each adjustment of the Warrant Price
and Shares, the Company shall promptly notify Holder in writing, and, at the Company’s expense, promptly compute such adjustment,
and furnish Holder with a certificate of its Chief Financial Officer, Corporate Secretary or a senior financial officer setting
forth such adjustment and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder
a certificate setting forth the Warrant Price and Shares in effect upon the date thereof and the series of adjustments leading
to such Warrant Price and Shares.


 


ARTICLE
3 REPRESENTATIONS AND COVENANTS OF THE COMPANY. The
Company represents, warrants and covenants to the Holder as follows:


 


3.1.         
Representations and Warranties. The Company represents and warrants and
covenants to the Holder as follows: All corporate action required to be taken by the Company’s Board of Directors and stockholders
in order to authorize the Company to enter into this Warrant, and to issue the Shares upon exercise thereof, has been taken. All
Shares which may be issued upon the exercise of the purchase right represented by this Warrant shall, upon issuance, be duly authorized,
validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on transfer provided
for herein or under applicable federal and state securities laws. The issuance of this Warrant, or the Shares issuable thereunder,
will not trigger any anti-dilution adjustment, preemptive rights, rights of first refusal or other similar rights of third parties
other than as have been waived prior to the issuance of this Warrant. The Company will at all times reserve and keep available,
out of its authorized but unissued share of Common Stock, solely for the purpose of providing the exercise or conversion of this
Warrant, the aggregate number of Shares issuable upon exercise or conversion of this Warrant. The Company will use its reasonable
best efforts to ensure that the Shares may be issued without violation of any law or regulation applicable to the Company or of
any requirement of any securities exchange applicable to the Company on which the Shares are listed or traded.


 


3.2.         
All corporate action required to be taken by the Company’s Board of Directors
and stockholders in order to authorize the Company to enter into this Warrant, and to issue the Shares at the closing, has been
taken or will be taken prior to the closing. All action on the part of the officers of the Company necessary for the execution
and delivery of this Warrant, the performance of all obligations of the Company under this Warrant to be performed as of the closing,
and the issuance and delivery of the Shares has been taken or will be taken prior to the closing. This Warrant, when executed
and delivered by the Company, shall constitute valid and legally binding obligations of the Company, enforceable against the Company
in accordance with their respective terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium,
fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’ rights
generally or (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable
remedies.


 






    	7



     


    







 


3.3.         
No Stockholder Rights. Except as provided in this Warrant, and other than
with regard to shares of the Company’s Common Stock acquired by Holder other than pursuant to the exercise of this Warrant,
the Holder will not have any rights as a stockholder of the Company until the exercise of this Warrant.


 


3.4.         
Charges, Taxes and Expenses. Issuance of certificates for Shares to the
Holder or the credit of the Shares to the Holder or the Holder’s designee with DTC upon the exercise or conversion of this
Warrant shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the
issuance of such certificates, all of which taxes and expenses shall be paid by the Company.


 


3.5.            
Notice of Certain Events. If the Company proposes at any time to:


 


(a)
declare any dividend or distribution upon the outstanding shares of Common Stock, whether in cash, property, stock, or other securities
and whether or not a regular cash dividend;


 


(b)
offer for subscription or sale pro rata to the holders of the outstanding shares of the Common Stock any additional shares of
any class or series of the Company’s capital stock (other than pursuant to contractual pre-emptive rights);


 


(c)
effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares
of Common Stock; or


 


(d)
effect an Acquisition or to liquidate, dissolve or wind up;


 


then, in
connection with each such event, the Company shall give Holder:


 


(1)
in the case of the matters referred to in (a) and (b) above, at least seven (7) business days prior written notice of the earlier
to occur of the effective date thereof or the date on which a record will be taken for such dividend, distribution, or subscription
rights (and specifying the date on which the holders of outstanding shares of Common Stock will be entitled thereto) or for determining
rights to vote, if any; and


 


(2)
in the case of the matters referred to in (c) and (d) above at least seven (7) business days prior written notice of the date
when the same will take place (and specifying the date on which the holders of outstanding shares of Common Stock will be entitled
to exchange their shares for the securities or other property deliverable upon the occurrence of such event and such reasonable
information as Holder may reasonably require regarding the treatment of this Warrant in connection with such event giving rise
to the notice).


 






    	8



     


    







 


The Company
will also provide information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s
accounting or reporting requirements.


 


ARTICLE
4 REPRESENTATIONS, WARRANTIES OF THE HOLDER. The
Holder represents and warrants to the Company as follows:


 


4.1.         
Purchase for Own Account. This Warrant and the securities to be acquired
upon exercise or conversion of this Warrant by the Holder will be acquired for investment for the Holders account, not as a nominee
or agent, and not with a view to the public resale or distribution within the meaning of the Securities Act of 1933, as amended
(the “Securities Act”), and the Holder has no present intention, and upon exercise or conversion will have
no intention, of selling or engaging in any public distribution of the same except pursuant to a registration or exemption. Holder
also represents that the Holder has not been formed for the specific purpose of acquiring this Warrant or the Shares.


 


4.2.         
Disclosure of Information. The Holder has received or has had full access
to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition
of this Warrant and its underlying securities. The Holder further has had an opportunity to ask questions and receive answers
from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain
additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or
expense) necessary to verify any information furnished to the Holder or to which the Holder has access.


 


4.3.         
Investment Experience. The Holder understands that the purchase of this
Warrant and its underlying securities involves substantial risk. The Holder has experience as an investor in securities of companies
in the development stage and acknowledges that the Holder can bear the economic risk of such Holder’s investment in this
Warrant and its underlying securities and has such knowledge and experience in financial or business matters that the Holder is
capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting
personal or business relationship with the Company and certain of its officers, directors or controlling persons of a nature and
duration that enables the Holder to be aware of the character, business acumen and financial circumstances of such persons.


 


4.4.         
Accredited Investor Status. The Holder is an “accredited investor”
within the meaning of Regulation D promulgated under the Securities Act.


 






    	9



     


    

4.5.         
Securities Act. The Holder understands that this Warrant and the Shares
issuable upon exercise or conversion hereof have not been registered under the Securities Act in reliance upon a specific exemption
therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed
herein. The Holder understands that this Warrant and the Shares issued upon any exercise or conversion hereof must be held indefinitely
unless subsequently registered under the Securities Act and qualified under applicable state securities laws, or unless exemption
from such registration and qualification are otherwise available. The Holder further understands that settlement of this Warrant
is to be made in Shares and, for the elimination of doubt, the fact that the Shares delivered on exercise of this Warrant will
not be registered under the Securities Act (as defined below) will not in any way require the Company to settle this Warrant otherwise
than in Shares, including without limitation, that there is no circumstance that would require the Company to settle this Warrant
in cash.


 


ARTICLE
5 MISCELLANEOUS.


 


5.1.         
Term. This Warrant will be exercisable in whole or in part at any time
and from time to time on or before the Expiration Date.


 


5.2.         
Automatic Cashless Exercise upon Expiration. In the
event that, upon the Expiration Date, the fair market value of one Share as determined in accordance with Section 1.3 above is
greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date
to be exercised pursuant to Section 1.3 above as to all Shares for which it shall not previously have been exercised.


 


5.3.         
Legends. This Warrant and the Shares shall be imprinted with a legend in
substantially the following form:


 


NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT
BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM
REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD
PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE
MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.


 


5.4.         
Compliance with Securities Laws on Transfer. This Warrant and the Shares
issuable upon exercise of this Warrant may not be transferred or assigned in whole or in part without compliance with applicable
federal and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment
representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The
Company shall not require Holder to provide an opinion of counsel if the transfer is to any affiliate of the Holder, provided
that any such transferee is an “accredited investor” as defined in Regulation D under the Securities Act; provided,
however, in any such transfer the transferee shall agree to be bound by the terms of this Warrant as if an original holder hereof.
Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability
of Rule 144 promulgated under the Securities Act.


 






    	10



     


    

5.5.         
Notices. All notices and other communications from the Company to the Holder,
or vice versa, shall be deemed delivered and effective when given personally or mailed by first-class registered or certified
mail, postage prepaid (or on the first business day after transmission by facsimile), at such address as may have been furnished
to the Company or the Holder, as the case may be, in writing by the Company or such Holder from time to time. Effective upon receipt
of the fully executed Warrant, all notices to the Holder shall be addressed as follows until the Company receives notice of a
change of address in connection with a transfer or otherwise:


 


Ginkgo
Bioworks, Inc.


27
Drydock Avenue, 8th Floor


Boston,
MA 02210


Attn: CEO


Attn: General Counsel


 


With a copy (which shall
not constitute notice) to:


 


Latham & Watkins
LLP


1000 Winter Street Suite
3700

Waltham, MA 02451

Attn:

Facsimile:


 


Notice to the Company shall be
addressed as follows until the Holder receives notice of a change in address:


 


Amyris, Inc.

5885 Hollis Street, Suite 100


Emeryville, CA 94608


Attn: General Counsel


Facsimile:


 


With a copy (which shall
not constitute notice) to:


 


Shearman & Sterling
LLP


535 Mission Street, 25th
Floor


San Francisco, CA 94105


Attn:


Facsimile:


 






    	11



     


    

 


5.6.         
Waiver. This Warrant and any term hereof may be changed, waived, discharged
or terminated only by an instrument in writing signed by the parties against which enforcement of such change, waiver, discharge
or termination is sought.


 


5.7.         
Counterparts. This Warrant may be executed in counterparts, all of which
together shall constitute one and the same agreement.


 


5.8.         
Amendment. This Warrant may be amended and the observance of any term of
this Warrant may be waived only with the written consent of the Company and the Holder.


 


5.9.         
Binding Effect. This Warrant shall be binding upon any successors or assigns
of the Company.


 


5.10.      
Governing Law. This Warrant, and the provisions, rights, obligations, and
conditions set forth herein, and the legal relations between the parties hereto, including all disputes and claims, whether arising
in contract, tort, or under statute, shall be governed by and construed in accordance with the laws of the State of Delaware without
giving effect to its conflict of law provisions.


 


ARTICLE
6 CERTAIN DEFINITIONS.


 


“Bloomberg”
means Bloomberg Financial Markets.


 


“Principal
Market” means The NASDAQ Stock Market.


 


“Trading
Day” means any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the
principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common
Stock is then traded; provided that “Trading Day” shall not include any day on which the Common Stock is scheduled
to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is suspended from trading during
the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing
time of trading on such exchange or market, then during the hour ending at 4:00 p.m., New York time).


 


“Marketable
Securities” means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting
requirements of Section 13 or Section 15(d) of the Exchange Act and is then current in its filing of all required reports and
other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that
would be received by Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing
thereof is then traded in a trading market, and (iii) following the closing of such Acquisition, Holder would not be restricted
from publicly re-selling all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition
were Holder to exercise this Warrant in full on or prior to the closing of such Acquisition, except to the extent that any such
restriction (x) arises solely under federal or state


securities laws, rules or regulations,
and (y) does not extend beyond six (6) months from the closing of such Acquisition.


 


[Balance
of Page Intentionally Left Blank]


 






    	12



     


    

 


	 	 	“COMPANY”
	 	 	 
	 	 	Amyris, Inc.
	 	 	 
	 	 	 
	 	 	By: 	/s/ John Melo
	 	 	 	John Melo, Chief Executive Officer
	 	 	 
	 	 	 
	AGREED AND ACKNOWLEDGED:	 	 
	“HOLDER”	 	 
	 	 	 
	Ginkgo Bioworks, Inc. 	 	 
	 	 	 
	 	 	 
	(Signature)	 	 
	 	 	 
	(Print Name)	 	 
	 	 	 
	(Title)	 	 






 


 


[Signature
Page to Warrant]



 






     


     


    




	 	 	“COMPANY”
	 	 	 
	 	 	Amyris, Inc.
	 	 	 
	 	 	 
	 	 	By: 	
	 	 	 	John Melo, Chief Executive Officer
	 	 	 
	 	 	 
	AGREED AND ACKNOWLEDGED:	 	 
	“HOLDER”	 	 
	 	 	 
	Ginkgo Bioworks, Inc. 	 	 
	 	 	 
	By:  	/s/ Jason Kelly	 	 
	 	Jason Kelly, Chief Executive Officer	 	 
		 	 



 


 






[Signature
Page to Warrant]






     


     


    




Exhibit
A


 


EXERCISE
NOTICE


 


TO
BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS

WARRANT TO PURCHASE COMMON STOCK


 


AMYRIS,
INC.


 


The
undersigned holder hereby exercises the right to purchase _________________ of the shares of Common Stock (“Shares”)
of Amyris, Inc., a Delaware corporation (the “Company”), evidenced by Warrant to Purchase Common Stock No. GW-1
(the “Warrant”). Capitalized terms used herein and not otherwise defined shall have the respective meanings
set forth in the Warrant.


 





	1.        Form
    of Warrant Price. The Holder intends that payment of the Aggregate Warrant Price shall be made as:
	 	 	 
	 	 	 	   	a “Cash Exercise” with respect to	 
	 	 	 	 	Shares; and/or	 
	 	 	 	 	 
	 	 	 	 	a “Cashless Exercise” with respect to	 
	 	 	 	 	Shares.	 
	 	 	 	 	 	 
	2.        Payment
    of Warrant Price. In the event that the Holder has elected a Cash Exercise with respect to some or all of the Shares to
    be issued pursuant hereto, the Holder shall pay the Aggregate Warrant Price in the sum of $___________________ to the Company
    in accordance with the terms of the Warrant.
	 
	3.        Delivery
    of Shares. The Company shall deliver to Holder, or its designee or agent as specified below, __________ Shares in accordance
    with the terms of the Warrant. Delivery shall be made to Holder, or for its benefit, as follows:
	 	 	 	 	 	 
	[_]   Check here if requesting delivery as a certificate to the following name and to the following address:
	 	 	 
	 	Issue
    to:  	 
	 	 	 
	 	 	 
	 	 	 
	[_]   Check here if requesting delivery
                                         by Deposit/Withdrawal at Custodian as follows:
	 	 	 
	 	DTC Participant:  	 
	 	 	 
	 	DTC Number:	 






















 






     


     


    




	 	 	 	 	 	 
	 	Account Number:       	 
	 	 	 
	 	 	 
	Date: 	 	 
	 	  	 
	 	 	 
	Name of Registered Holder	 
	 	 
	By: 		 
	 	Name:	 
	 	Title:	 
	 	 	 
	 	Tax
        ID:	                                                         	 
	 	Facsimile:	 	 
	 	E-mail
        Address: